Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas.

Abstract:

:A heterogeneous group of malignancies are associated with Epstein-Barr virus (EBV) infection. These malignancies arise in both immunosuppressed and immunocompetent individuals and can be divided into three patterns of latency depending on the viral genes that are expressed. In Type III latency malignancies, such as post-transplant lymphoproliferative disorder (PTLD), EBV has a direct role and the activated B-cell phenotype is characterised by high-level expression of all the immunodominant EBV latency proteins. Thus, EBV-infected B cells are good targets for EBV-specific cytotoxic T lymphocytes (CTLs). New immune-based treatments for PTLD include transfer of ex vivo generated autologous EBV-specific CTLs or, in the case of bone marrow transplant recipients, donor-derived EBV-specific T cells. This strategy could, perhaps, also work in Type II latency malignancies, where EBV acts like a cofactor rather than having a direct role. In initial studies, T cells specific for the weakly immunogenic latent membrane protein 2 have been expanded ex vivo and have promoted tumor regression in a subset of patients. Another potential therapeutic strategy could be to try to induce lytic EBV infection in the tumor cells. This could be done by targeting genes that switch the EBV-infected B cells from the latent to the lytic cycle.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Cohen JI,Bollard CM,Khanna R,Pittaluga S

doi

10.1080/10428190802311417

subject

Has Abstract

pub_date

2008-01-01 00:00:00

pages

27-34

eissn

1042-8194

issn

1029-2403

pii

903037021

journal_volume

49 Suppl 1

pub_type

杂志文章,评审
  • Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.

    abstract::High-dose therapy (HDT) is now recommended for patients under 60 years of age with chemosensitive relapsed aggressive non-Hodgkin's lymphoma. However, approximately half of these patients will be cured by HDT. Prognostic factors are needed to predict which patients with chemosensitive lymphoma to second-line therapy c...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500054350

    authors: Jabbour E,Peslin N,Arnaud P,Ferme C,Carde P,Vantelon JM,Bocaccio C,Bourhis JH,Koscielny S,Ribrag V

    更新日期:2005-06-01 00:00:00

  • Coexistence of chronic lymphocytic leukemia and essential thrombocythemia.

    abstract::The association of chronic lymphocytic leukemia (CLL) with essential thrombocythemia (ET) is an extremely rare event and until now 3 patients with such coexistence have been reported in the literature. We report a 77-year-old white woman in whom these two disorders were diagnosed concomitantly on the basis of peripher...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819031000097348

    authors: Robak T,Urbańska-Ryś H,Góra-Tybor J,Wawrzyniak E,Korycka A,Bartkowiak J,Kordek R,Polliack A

    更新日期:2003-08-01 00:00:00

  • Diagnostic imaging in the evaluation of renal lymphoma.

    abstract::Renal lymphoma usually is a manifestation of disseminated disease and often is asymptomatic. Occasionally, the kidney(s) may be the major or only demonstrable site of disease, which may then present with a variety of urologic symptoms. The imaging studies should be tailored according to the presenting symptoms and pri...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199409114138

    authors: Eisenberg PJ,Papanicolaou N,Lee MJ,Yoder IC

    更新日期:1994-12-01 00:00:00

  • Clonality assays and megakaryocyte culture techniques in essential thrombocythemia.

    abstract::The development of techniques permitting in vitro growth of human megakaryocytes progenitors and more recently identification of the proto oncogene c-mpl (Mpl-R) and its ligand (Mpl-L) have created new opportunities for studying pathophysiology of E.T. Plasma or serum of E.T. patients was unable to overestimulate MK c...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199609074358

    authors: Yan L,Elkassar N,Gardin C,Briere J

    更新日期:1996-09-01 00:00:00

  • Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia.

    abstract::We retrospectively studied 87 patients aged from 55 to 69 years old with acute myeloid leukemia (AML) who received decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin (DCAG) or standard dose chemotherapy as induction therapy. Patients receiving DCAG had a similar overall response rate (ORR) (p = ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1443328

    authors: Huang J,Hong M,Zhu Y,Zhao H,Zhang X,Wu Y,Lian Y,Zhao X,Li J,Qian S

    更新日期:2018-11-01 00:00:00

  • The dose related effect of steroids on blast reduction rate and event free survival in children with acute lymphoblastic leukemia.

    abstract::We examined the effect of high-dose methylprednisolone (HDMP) on blast reduction rate and compared it to conventional dose steroid treatment, administered during the first 7+ days of the induction remission period in patients with acute lymphoblastic leukemia (ALL). In our previous randomized study, the event free sur...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1080/1042819021000055048

    authors: Yetgin S,Cetin M

    更新日期:2003-03-01 00:00:00

  • Etiology, clinical course and outcome of healthcare-associated bloodstream infections in patients with hematological malignancies: a retrospective study of 350 patients in a Finnish tertiary care hospital.

    abstract::This retrospectively collected laboratory-based surveillance data includes 575 healthcare-associated bloodstream infections (BSIs) in 350 patients with hematological malignancy in Tampere University Hospital, Finland, during 1999-2001 and 2005-2010. The most common underlying diseases were acute myelogenous leukemia (...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1032967

    authors: Åttman E,Aittoniemi J,Sinisalo M,Vuento R,Lyytikäinen O,Kärki T,Syrjänen J,Huttunen R

    更新日期:2015-01-01 00:00:00

  • Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis.

    abstract::Recently, lenalidomide and low dose dexamethasone were found to result in superior overall survival compared to lenalidomide and high dose dexamethasone. The immune suppressive effects of dexamethasone can antagonize lenalidomide immunomodulatory activity and may explain this observation. We conducted a retrospective ...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.3109/10428191003721342

    authors: Baz R,Patel M,Finley-Oliver E,Lebovic D,Hussein MA,Miller KC,Wood M,Sher T,Lee K,Chanan-Khan AA

    更新日期:2010-06-01 00:00:00

  • Thymidylate synthase polymorphisms and hematological cancer risk: a meta-analysis.

    abstract::Previous studies on the association of Thymidylate synthase (TYMS) polymorphisms with risk of hematological malignancies have produced conflicting results. The purpose of this meta-analysis was to define the effect of TYMS 5'-untranslated enhanced region (TSER) and 3'-untranslated region (TS3'-UTR) polymorphisms on th...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2011.649477

    authors: Weng Y,Zhang J,Tang X,Xie X,Chen G

    更新日期:2012-07-01 00:00:00

  • BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group.

    abstract::Patients with early stage favorable Hodgkin's disease who relapse after extended field radiotherapy have satisfactory results. We retrospectively analysed patients with relapsed HD after initial radiation therapy alone to determine treatment outcome and prognostic factors. Nine-hundred and forty five patients in local...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500178167

    authors: Rüffer JU,Ballova V,Glossmann J,Sieber M,Franklin J,Nogova L,Diehl V,Josting A,German Hodgkin Study Group.

    更新日期:2005-11-01 00:00:00

  • Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy.

    abstract::An increasing incidence of Pneumocystis jiroveci pneumonia (PCP) in patients with B-cell non-Hodgkin lymphoma (B-NHL) receiving rituximab treatment has been reported. We reviewed patients with B-NHL who underwent chemotherapy from 2004 to 2008 at our institution to identify risk factors for PCP development during and ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.506569

    authors: Hashimoto K,Kobayashi Y,Asakura Y,Mori M,Azuma T,Maruyama D,Kim SW,Watanabe T,Tobinai K

    更新日期:2010-10-01 00:00:00

  • Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's Lymphoma?

    abstract::We attempted to analyze whether the use of high-dose cyclophosphamide (CTX 7g/m2, group A) plus hematopoietic growth factor (G-CSF) or G-CSF alone (10 microg/Kg, group B) as a mobilizing regimen, could result in harvesting different numbers of CD34+ cells, committed progenitors and CD34+ cells subsets. The number of C...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009065829

    authors: Dazzi C,Cariello A,Rosti G,Argnani M,Sebastiani L,Ferrari E,Zornetta L,Monti G,Nicoletti P,Baioni M,Salvucci M,Scarpi E,Marangolo M

    更新日期:2000-10-01 00:00:00

  • Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.

    abstract::Inhibiting the activity of Bruton tyrosine kinase (BTK) prevents the activation of the B-cell receptor (BCR) signaling pathway, which in turn prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. Acalabrutinib is an orally available, highly selective, next-generation inhibitor of...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1864352

    authors: Ghia P,Dlugosz-Danecka M,Scarfò L,Jurczak W

    更新日期:2021-01-11 00:00:00

  • Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma.

    abstract::We describe a patient with natural killer (NK)/T cell lymphoma who relapsed after autologous peripheral blood stem cell transplantation (auto-PBSCT) and was successfully treated with Escherichia coli (E. coli) and Erwinia L-asparaginase. A 38-year-old male patient with ulcerated tumor at the left thigh was diagnosed a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819031000067873

    authors: Matsumoto Y,Nomura K,Kanda-Akano Y,Fujita Y,Nakao M,Ueda K,Horiike S,Yokota S,Kusuzaki K,Kitoh T,Watanabe A,Taniwaki M

    更新日期:2003-05-01 00:00:00

  • Leukoencephalopathy in childhood acute lymphoblastic leukemia with t(1;19).

    abstract::To clarify the incidence of leukoencephalopathy in patients with t(1;19) and their clinical characteristics, we studied 239 acute lymphoblastic leukemia (ALL) cases. The 1;19 translocation was found in 20 (8.5%) of the 239 children with ALL. Leukoencephalopathy occurred in 2 (10%) patients with t(1;19) during the earl...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909093734

    authors: Shikano T,Kobayashi R,Ishikawa Y

    更新日期:1999-03-01 00:00:00

  • Treatment of post-transplanted, relapsed patients with hematological malignancies by infusion of HLA-matched, allogeneic-dendritic cells (DCs) pulsed with irradiated tumor cells and primed T cells.

    abstract::Patients with hematological malignancies who relapse after bone marrow transplantation (BMT) are often treated with donor lymphocyte infusion. However, this procedure often results in graft-versus-host disease (GVHD). While, Dendritic cells (DCs), which present antigens to naive T cells, have been used in the immunoth...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428190109064592

    authors: Fujii S,Shimizu K,Fujimoto K,Kiyokawa T,Tsukamoto A,Sanada I,Kawano F

    更新日期:2001-07-01 00:00:00

  • Transcobalamin II and in vitro proliferation of leukemic cells.

    abstract::We have recently shown that antibodies to transcobalamin II (TCII) inhibit the in vitro growth of human and murine leukemic cells. This antiproliferative strategy targets the uptake of cobalamin (Cbl), an essential cofactor for two biochemical reactions in humans. To date there has been no appropriate cell culture mod...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199809050933

    authors: McLean GR,Williams MJ,Woodhouse CS,Ziltener HJ

    更新日期:1998-06-01 00:00:00

  • A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.

    abstract::Anti-B4-blocked ricin (anti-B4-bR) is a potent immunotoxin directed against the CD19 antigen. Previous phase I and II studies suggested a possible role for anti-B4-bR as consolidation after high-dose chemotherapy and autologous stem cell transplant. Cancer and Leukemia Group B (CALGB) 9254 is a phase III study which r...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.3109/10428194.2010.543714

    authors: Furman RR,Grossbard ML,Johnson JL,Pecora AL,Cassileth PA,Jung SH,Peterson BA,Nadler LM,Freedman A,Bayer RL,Bartlett NL,Hurd DD,Cheson BD,Cancer Leukemia Group B.,Eastern Cooperative Oncology Group.

    更新日期:2011-04-01 00:00:00

  • Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant.

    abstract::Infection, relapse, and GVHD can complicate allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although the effect of poor immune recovery on infection risk is well-established, there are limited data on the effect of immune reconstitution on relapse and survival, especially following T-cell depletion (TC...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1265113

    authors: Goldberg JD,Zheng J,Ratan R,Small TN,Lai KC,Boulad F,Castro-Malaspina H,Giralt SA,Jakubowski AA,Kernan NA,O'Reilly RJ,Papadopoulos EB,Young JW,van den Brink MR,Heller G,Perales MA

    更新日期:2017-08-01 00:00:00

  • P-Glycoprotein Expression in Drug-Resistant Chronic Lymphoproliferative Disorder.

    abstract::Peripheral blood lymphocytes from 60 patients with drug-resistant chronic lymphoproliferative disorders (LPD) were examined for expression of P-glycoprotein (P-gp) by direct immunofluorescence (IF) test using monoclonal antibody (MoAb) C219. Four of the 15 patients with prolymphocytic leukaemia (PLL), and both patient...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109067633

    authors: Majumdar G,Singh AK

    更新日期:1991-01-01 00:00:00

  • Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis.

    abstract::Tumor-infiltrating immune cells perform a crucial function in host immune reactions against diffuse large B-cell lymphoma (DLBCL). In this study, we have identified a subset of tumor-infiltrating FOXP3-positive regulatory T cells (Tregs) in the initial DLBCL biopsy specimens, and have evaluated their prognostic signif...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701824536

    authors: Lee NR,Song EK,Jang KY,Choi HN,Moon WS,Kwon K,Lee JH,Yim CY,Kwak JY

    更新日期:2008-02-01 00:00:00

  • Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older.

    abstract::In the rituximab era, several large studies have suggested that full-dose rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) might be the best treatment for patients with diffuse large B-cell lymphoma (DLBCL) aged 60 years and older. However, it remains unclear whether this is also the c...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.600486

    authors: Meguro A,Ozaki K,Sato K,Oh I,Fujiwara S,Hosonuma R,Sasazaki M,Kikuchi Y,Hirata Y,Yamamoto C,Uesawa M,Kobayashi H,Matsu H,Okabe H,Uehara E,Nishikawa A,Tatara R,Hatano K,Yamamoto C,Matsuyama T,Toshima M,Ueda M,O

    更新日期:2012-01-01 00:00:00

  • Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group.

    abstract::This study was planned as a phase 3 trial to investigate low-dose fludarabine with or without darbepoetin alfa in older patients with previously untreated or treated chronic lymphocytic leukemia (CLL) and comorbidity. Due to slow recruitment, the study was terminated prematurely after accrual of 97 patients who, on av...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.3109/10428194.2015.1079314

    authors: Goede V,Busch R,Bahlo J,Chataline V,Kremers S,Müller L,Reschke D,Schlag R,Schmidt B,Vehling-Kaiser U,Wedding U,Stilgenbauer S,Hallek M

    更新日期:2016-01-01 00:00:00

  • Surgical treatment of acute abdominal complications in hematology patients: outcomes and prognostic factors.

    abstract::The decision to operate on hematology patients with abdominal emergencies can be difficult, as neutropenia and thrombocytopenia are common and the usual causes of abdominal pain are broad. We conducted a retrospective observational study including all hematology patients undergoing emergency abdominal surgery between ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1296145

    authors: Mokart D,Penalver M,Chow-Chine L,Ewald J,Sannini A,Brun JP,Bisbal M,Lelong B,Delpero JR,Faucher M,Turrini O

    更新日期:2017-10-01 00:00:00

  • The emerging role of immune checkpoint based approaches in AML and MDS.

    abstract::The development of immune checkpoint inhibitors represents a major breakthrough in the field of cancer therapeutics. Pursuant to their success in melanoma and numerous solid tumor malignancies, these agents are being investigated in hematological malignancies including acute myelogenous leukemia (AML) and myelodysplas...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2017.1344905

    authors: Boddu P,Kantarjian H,Garcia-Manero G,Allison J,Sharma P,Daver N

    更新日期:2018-04-01 00:00:00

  • Targeting the bone marrow microenvironment in acute leukemia.

    abstract::Despite individual differences between certain leukemias, the overall survival rate in acute leukemia remains low at approximately 40%. Novel therapeutics, including targeted therapies like tyrosine kinase inhibitors, have been incorporated into treatment regimens, but most have failed at eradicating leukemic stem cel...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2018.1434886

    authors: Karantanou C,Godavarthy PS,Krause DS

    更新日期:2018-11-01 00:00:00

  • Prevention and treatment of hepatic venocclusive disease after high-dose cytoreductive therapy.

    abstract::Venocclusive disease of the liver (VOD) is one of the most common and serious complications following stem cell transplantation. High-dose chemotherapy or chemoradiotherapy injures the structures of Zone 3 of the liver acinus and produces the clinical syndrome of hepatomegaly or right upper quadrant pain, jaundice, an...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199809059219

    authors: Richardson P,Bearman SI

    更新日期:1998-10-01 00:00:00

  • CD31/PECAM-1 impacts engraftment, growth and spread of mantle cell lymphoma cells and positively correlates with extramedullary involvement.

    abstract::Platelet/endothelial cell adhesion molecule 1 (PECAM-1, CD31) is an immunoglobulin superfamily member expressed on the surface of platelets, leukocytes and endothelial cells. The role of CD31 in biology of lymphomas has not yet been systemically studied. Expression of cell surface CD31 was analyzed by flow cytometry o...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1849678

    authors: Vockova P,Molinsky J,Klanova M,Karban J,Spacek M,Havranek O,Kupcova K,Kazantsev D,Trneny M,Klener P

    更新日期:2020-11-25 00:00:00

  • Efficacy of selective digestive decontamination in patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell transplantation.

    abstract::Selective digestive decontamination (SDD) with the oral, non-absorbable antimicrobial substances gentamicin, vancomycin and amphotericin B was optionally used at our institution to reduce the risk of gastrointestinal tract derived infections in multiple myeloma (MM) patients undergoing high-dose chemotherapy with subs...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1496332

    authors: Mürner CM,Stenner-Liewen F,Seifert B,Mueller NJ,Schmidt A,Renner C,Schanz U,Knuth A,Manz MG,Scharl M,Gerber B,Samaras P

    更新日期:2019-03-01 00:00:00

  • Acute Megakaryoblastic Leukemia: Importance of Bone Marrow Biopsy in Diagnosis.

    abstract::Five cases of megakaryoblastic leukemia, presenting as "de novo" acute leukemias are reported. They represented 7.2% of all cases of adult acute non-lymphoblastic leukemias (ANLL) seen in our Hematology Service during the past 30 months. These cases showed features of predominantly blast proliferation with a marked in...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109107060

    authors: Lorand-Metze I,Vassallo J,Aoki RY,De Souza CA

    更新日期:1991-01-01 00:00:00